Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis
Alex Castañeda-Sabogal, Diego Chambergo-Michilot, Carlos J Toro-Huamanchumo, Christian Silva-Rengifo, José Gonzales-Zamora, Joshuan J Barboza
doi:10.1101/2021.01.26.21250420
Background: To assess the outcomes of ivermectin in ambulatory and hospitalized patients with COVID-19. Methods: Five databases and websites for preprints were searched until January 2021 for randomized controlled trials (RCTs) and retrospective cohorts assessing ivermectin versus control in ambulatory and hospitalized participants. The primary outcome was overall mortality. Secondary outcome was recovered patients. For meta-analysis, random-effects and inverse variance meta-analyses with logarithmic transformation were performed. ROBINS-I for cohort studies, and the Cochrane Risk of Bias 2.0 tool for trials were used. The strength of evidence was assessed using GRADE. Results. After the selection, twelve studies (five retrospective cohort studies, six randomized clinical trials and one case series), were included. In total, 7412 participants were reported, the mean age was 47.5 (SD 9.5) years, and 4283 (58%) were male. Ivermectin was not associated with reduced mortality (logRR: 0.89, 95% CI 0.09 to 1.70, p = 0.04, I 2 = 84.7%), or reduced patient recovery (logRR 5.52 , 95% CI -24.36 to 35.4, p = 0.51, I 2 = 92.6%). All studies had a high risk of bias, and showed a very low certainty of the evidence. Conclusions: There insufficient certainty and quality of evidence to recommend the use of ivermectin to prevent or treat ambulatory or hospitalized patients with COVID-19.
References
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
Banerjee, Nandy, Dalai, Ahmed, The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin, Drug Res (Stuttg)
Bray, Rayner, Noel, Jans, Wagstaff, Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Camprubi, Almuedo-Riera, Marti-Soler, Soriano, Hurtado et al., Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PLoS ONE
Carvallo, Hirsch, Farinella, Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19, medRxiv
Castillo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebocontrolled, randomized clinical trial, EClinicalMedicine
Cepelowicz, Sherman, Fatteh, Vogel, Sacks et al., ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19, medRxiv
Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., None
Chirinos, Vf, Heresi-Dávila, Hernandez, Málaga et al., Sobre las recomendaciones del Ministerio de Salud para el tratamiento farmacológico de la COVID-19 en el Perú, Acta Médica Peruana
Dixit, Yadav, Singh, Ivermectin: Potential Role as Repurposed Drug for COVID-19, Malays J Med Sci
Formiga, Leblanc, De Souza Reboucas, Farias, De Oliveira et al., Ivermectin: an award-winning drug with expected antiviral activity against COVID-19, J Control Release
Gorial, Mashhadani, Sayaly, Dakhil, Almashhadani et al., Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management, Pilot Trial
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot
Higgins, Thompson, Deeks, Altman, Measuring inconsistency in metaanalyses, BMJ (Clinical research ed
Higgins, Tj, Chandler, Cumpston, Li et al., Chapter 24: Including non-randomized studies on intervention effects
Khan, Khan, Debnath, Nath, Mahtab et al., Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19
Kim, An, Kim, Hwang, Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis, PLoS Med
Marcolino, Pimentel, Barao, What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results, Eur J Pharmacol
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis, J Pharm Pharm Sci
Page, Mckenzie, Bossuyt, Boutron, Hoffmann et al., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Podder, Nc, Ibne Sina, Md Mohosin, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study, IMC Journal of Medical Science
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease, The ICON Study
Schmith, Zhou, Lohmer, The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19, Clin Pharmacol Ther
Schünemann, Bj, Guyatt, Oxman, GRADE handbook for grading quality of evidence and strength of recommendations
Shakhsi Niaee, Ng, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
Soto-Becerra, Culquichicon, Hurtado-Roca, Araujo-Castillo, Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru, medRxiv
Sterne, Hernán, Reeves, Savović, Berkman et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ (Clinical research ed
Sterne, Savović, Page, Elbers, Blencowe et al., RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ
Waheed, Prophylactic Ivermectin in COVID-19 Contacts -Study Results -ClinicalTrials
Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review, JAMA
DOI record:
{
"DOI": "10.1101/2021.01.26.21250420",
"URL": "http://dx.doi.org/10.1101/2021.01.26.21250420",
"abstract": "<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>To assess the outcomes of ivermectin in ambulatory and hospitalized patients with COVID-19.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Five databases and websites for preprints were searched until January 2021 for randomized controlled trials (RCTs) and retrospective cohorts assessing ivermectin versus control in ambulatory and hospitalized participants. The primary outcome was overall mortality. Secondary outcome was recovered patients. For meta-analysis, random-effects and inverse variance meta-analyses with logarithmic transformation were performed. ROBINS-I for cohort studies, and the Cochrane Risk of Bias 2.0 tool for trials were used. The strength of evidence was assessed using GRADE.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>After the selection, twelve studies (five retrospective cohort studies, six randomized clinical trials and one case series), were included. In total, 7412 participants were reported, the mean age was 47.5 (SD 9.5) years, and 4283 (58%) were male. Ivermectin was not associated with reduced mortality (logRR: 0.89, 95% CI 0.09 to 1.70, p = 0.04, I<jats:sup>2</jats:sup>= 84.7%), or reduced patient recovery (logRR 5.52, 95% CI -24.36 to 35.4, p = 0.51, I<jats:sup>2</jats:sup>= 92.6%). All studies had a high risk of bias, and showed a very low certainty of the evidence.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>There insufficient certainty and quality of evidence to recommend the use of ivermectin to prevent or treat ambulatory or hospitalized patients with COVID-19.</jats:p></jats:sec>",
"accepted": {
"date-parts": [
[
2021,
1,
27
]
]
},
"author": [
{
"affiliation": [],
"family": "Castañeda-Sabogal",
"given": "Alex",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0002-3904-7514",
"affiliation": [],
"authenticated-orcid": false,
"family": "Chambergo-Michilot",
"given": "Diego",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-4664-2856",
"affiliation": [],
"authenticated-orcid": false,
"family": "Toro-Huamanchumo",
"given": "Carlos J.",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-7261-7702",
"affiliation": [],
"authenticated-orcid": false,
"family": "Silva-Rengifo",
"given": "Christian",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-2768-9712",
"affiliation": [],
"authenticated-orcid": false,
"family": "Gonzales-Zamora",
"given": "José",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-2896-1407",
"affiliation": [],
"authenticated-orcid": false,
"family": "Barboza",
"given": "Joshuan J.",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
1,
27
]
],
"date-time": "2021-01-27T16:45:26Z",
"timestamp": 1611765926000
},
"deposited": {
"date-parts": [
[
2021,
4,
22
]
],
"date-time": "2021-04-22T07:48:09Z",
"timestamp": 1619077689000
},
"group-title": "Infectious Diseases (except HIV/AIDS)",
"indexed": {
"date-parts": [
[
2023,
8,
30
]
],
"date-time": "2023-08-30T18:59:28Z",
"timestamp": 1693421968019
},
"institution": [
{
"name": "medRxiv"
}
],
"is-referenced-by-count": 9,
"issued": {
"date-parts": [
[
2021,
1,
27
]
]
},
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1101/2021.01.26.21250420",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "246",
"original-title": [],
"posted": {
"date-parts": [
[
2021,
1,
27
]
]
},
"prefix": "10.1101",
"published": {
"date-parts": [
[
2021,
1,
27
]
]
},
"publisher": "Cold Spring Harbor Laboratory",
"reference": [
{
"DOI": "10.1055/a-1185-8913",
"article-title": "The Battle against COVID 19 Pandemic: What we Need to Know Before we “Test Fire” Ivermectin",
"doi-asserted-by": "crossref",
"first-page": "337",
"issue": "8",
"journal-title": "Drug Res (Stuttg)",
"key": "2021012909450808000_2021.01.26.21250420v1.1",
"volume": "70",
"year": "2020"
},
{
"DOI": "10.1001/jama.2020.12839.e4",
"doi-asserted-by": "publisher",
"key": "2021012909450808000_2021.01.26.21250420v1.2"
},
{
"article-title": "Ivermectin: Potential Role as Repurposed Drug for COVID-19",
"first-page": "154",
"issue": "4",
"journal-title": "Malays J Med Sci",
"key": "2021012909450808000_2021.01.26.21250420v1.3",
"volume": "27",
"year": "2020"
},
{
"DOI": "10.1038/s41429-020-0336-z",
"article-title": "Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen",
"doi-asserted-by": "crossref",
"first-page": "593",
"issue": "9",
"journal-title": "J Antibiot (Tokyo)",
"key": "2021012909450808000_2021.01.26.21250420v1.4",
"volume": "73",
"year": "2020"
},
{
"DOI": "10.1016/j.antiviral.2020.104787",
"article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro",
"doi-asserted-by": "crossref",
"first-page": "104787",
"journal-title": "Antiviral Res",
"key": "2021012909450808000_2021.01.26.21250420v1.5",
"volume": "178",
"year": "2020"
},
{
"DOI": "10.1002/cpt.1889",
"article-title": "The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19",
"doi-asserted-by": "crossref",
"first-page": "762",
"issue": "4",
"journal-title": "Clin Pharmacol Ther",
"key": "2021012909450808000_2021.01.26.21250420v1.6",
"volume": "108",
"year": "2020"
},
{
"DOI": "10.31222/osf.io/jb4dx",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.7",
"unstructured": "Page M , McKenzie J , Bossuyt P , Boutron I , Hoffmann T , Mulrow C , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. MetaArXiv Preprints. 2020."
},
{
"DOI": "10.1136/bmj.i4919",
"doi-asserted-by": "publisher",
"key": "2021012909450808000_2021.01.26.21250420v1.8"
},
{
"DOI": "10.1136/bmj.l4898",
"doi-asserted-by": "publisher",
"key": "2021012909450808000_2021.01.26.21250420v1.9"
},
{
"key": "2021012909450808000_2021.01.26.21250420v1.10",
"unstructured": "Schünemann H BJ , Guyatt G , Oxman A , editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Group GW , editor. USA: GRADE Working Group; 2013."
},
{
"DOI": "10.1136/bmj.327.7414.557",
"doi-asserted-by": "publisher",
"key": "2021012909450808000_2021.01.26.21250420v1.11"
},
{
"DOI": "10.1002/9781119536604",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.12",
"unstructured": "Higgins JPT TJ , Chandler J , Cumpston M , Li T , Page MJ , Welch VA . Cochrane Handbook for Systematic Reviews of Interventions. Chapter 24: Including non-randomized studies on intervention effects. Cochrane. 2020;Available from www.training.cochrane.org/handbook."
},
{
"article-title": "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness",
"first-page": "214",
"journal-title": "Int J Infect Dis",
"key": "2021012909450808000_2021.01.26.21250420v1.13",
"volume": "103",
"year": "2020"
},
{
"DOI": "10.1371/journal.pone.0242184",
"doi-asserted-by": "publisher",
"key": "2021012909450808000_2021.01.26.21250420v1.14"
},
{
"DOI": "10.1101/2020.09.10.20191619",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.15",
"unstructured": "Carvallo HE , Hirsch RR , Farinella ME . Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. medRxiv. 2020:2020.09.10.20191619."
},
{
"DOI": "10.1101/2020.07.07.20145979",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.16",
"unstructured": "Gorial FI , Mashhadani S , Sayaly HM , Dakhil BD , AlMashhadani MM , Aljabory AM , et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). medRxiv. 2020:2020.07.07.20145979."
},
{
"DOI": "10.1016/j.arbres.2020.12.013",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.17",
"unstructured": "Khan SI , Khan SI , Debnath CR , Nath PN , Mahtab MA , Nabeka H , et al. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Archivos de Bronconeumología (English Edition). 2020."
},
{
"key": "2021012909450808000_2021.01.26.21250420v1.18",
"unstructured": "Mahmud R. A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care. Clinical trial registration. U.S. National Library of Medicine. Clinical Trials; 2020 2020/10/07/. Report No.: results/NCT04523831."
},
{
"key": "2021012909450808000_2021.01.26.21250420v1.19",
"unstructured": "Morteza Shakhsi Niaee NG , et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. 2020."
},
{
"DOI": "10.3329/imcjms.v14i2.52826",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.20",
"unstructured": "Podder CH NC, Mohim Ibne Sina, Wasim Md Mohosin Ul Haque. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. IMC Journal of Medical Science. 2020;14(2)."
},
{
"DOI": "10.1101/2020.06.06.20124461",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.21",
"unstructured": "Rajter JC , Sherman MS , Fatteh N , Vogel F , Sacks J , Rajter JJ . Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The ICON Study. Chest. 2020."
},
{
"key": "2021012909450808000_2021.01.26.21250420v1.22",
"unstructured": "Waheed S. Prophylactic Ivermectin in COVID-19 Contacts - Study Results - ClinicalTrials.gov. US National Library of Medicine Clinical Trials. 2020."
},
{
"DOI": "10.2139/ssrn.3710623",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.23",
"unstructured": "Soto-Becerra P , Culquichicon C , Hurtado-Roca Y , Araujo-Castillo RV . Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru. medRxiv. 2020:2020.10.06.20208066."
},
{
"DOI": "10.1016/j.eclinm.2020.100720",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.24",
"unstructured": "Chaccour C , Casellas A , Blanco-Di Matteo A , Pineda I , Fernandez-Montero A , Ruiz-Castillo P , et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021:100720."
},
{
"key": "2021012909450808000_2021.01.26.21250420v1.25",
"unstructured": "Cepelowicz J , Sherman M , Fatteh N , Vogel F , Sacks J , Rajter J-J. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv. 2020:2020.06.06.20124461."
},
{
"article-title": "Epidemiology, problems, unit policies and opinions of healthcare workers",
"author": "Nosocomial infections in neonatal units in Turkey",
"first-page": "50",
"issue": "1",
"journal-title": "Turkish Journal of Pediatrics",
"key": "2021012909450808000_2021.01.26.21250420v1.26",
"volume": "52",
"year": "2010"
},
{
"DOI": "10.1016/j.jconrel.2020.10.009",
"doi-asserted-by": "crossref",
"key": "2021012909450808000_2021.01.26.21250420v1.27",
"unstructured": "Formiga FR , Leblanc R , de Souza Reboucas J , Farias LP , de Oliveira RN , Pena L. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. J Control Release. 2020."
},
{
"article-title": "Sobre las recomendaciones del Ministerio de Salud para el tratamiento farmacológico de la COVID-19 en el Perú",
"first-page": "231",
"journal-title": "Acta Médica Peruana",
"key": "2021012909450808000_2021.01.26.21250420v1.28",
"volume": "37",
"year": "2020"
},
{
"DOI": "10.1016/j.ejphar.2020.173467",
"doi-asserted-by": "publisher",
"key": "2021012909450808000_2021.01.26.21250420v1.29"
},
{
"DOI": "10.18433/jpps31457",
"article-title": "Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis",
"doi-asserted-by": "crossref",
"first-page": "462",
"journal-title": "J Pharm Pharm Sci",
"key": "2021012909450808000_2021.01.26.21250420v1.30",
"volume": "23",
"year": "2020"
},
{
"DOI": "10.1371/journal.pmed.1003501",
"article-title": "Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis",
"doi-asserted-by": "crossref",
"first-page": "e1003501",
"issue": "12",
"journal-title": "PLoS Med",
"key": "2021012909450808000_2021.01.26.21250420v1.31",
"volume": "17",
"year": "2020"
},
{
"DOI": "10.1016/j.antiviral.2020.104805",
"doi-asserted-by": "publisher",
"key": "2021012909450808000_2021.01.26.21250420v1.32"
},
{
"DOI": "10.1016/j.bjid.2020.06.002",
"article-title": "Ivermectin: potential candidate for the treatment of Covid 19",
"doi-asserted-by": "crossref",
"first-page": "369",
"issue": "4",
"journal-title": "Braz J Infect Dis",
"key": "2021012909450808000_2021.01.26.21250420v1.33",
"volume": "24",
"year": "2020"
},
{
"DOI": "10.1186/s13063-020-04988-7",
"article-title": "The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial",
"doi-asserted-by": "crossref",
"first-page": "4",
"issue": "1",
"journal-title": "Trials",
"key": "2021012909450808000_2021.01.26.21250420v1.34",
"volume": "22",
"year": "2021"
}
],
"reference-count": 34,
"references-count": 34,
"relation": {},
"resource": {
"primary": {
"URL": "http://medrxiv.org/lookup/doi/10.1101/2021.01.26.21250420"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"subtype": "preprint",
"title": "Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis",
"type": "posted-content"
}
